慢性心力衰竭患者血清可溶性Fas配体和可溶性Fas受体水平

李刚; 魏良明; 邓翠华; 陈运贞

doi:10.13406/j.cnki.cyxb.2003.01.013

您当前的位置：

首页 >

文章列表页 >

慢性心力衰竭患者血清可溶性Fas配体和可溶性Fas受体水平

更新时间：2024-01-17

- 慢性心力衰竭患者血清可溶性Fas配体和可溶性Fas受体水平
- The serum levels of soluble Fas ligand and soluble Fas receptor in patients with chronic congestive heart failure
- 重庆医科大学学报 2003年第1期页码：43-45
- 作者机构：
  
  1. 重庆医科大学第二临床学院心血管内科
  2. 重庆医科大学临床学院心血管内科,重庆,400010
  3. ,重庆,400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.2003.01.013
  中图分类号： R541.6
- 纸质出版日期：2003，
扫描看全文
[1]李刚,魏良明,邓翠华,陈运贞.慢性心力衰竭患者血清可溶性Fas配体和可溶性Fas受体水平[J].重庆医科大学学报,2003(01):43-45.

LI Gang, et al. The serum levels of soluble Fas ligand and soluble Fas receptor in patients with chronic congestive heart failure[J]. Journal of Chongqing Medical University, 2003,(1):43-45.
[1]李刚,魏良明,邓翠华,陈运贞.慢性心力衰竭患者血清可溶性Fas配体和可溶性Fas受体水平[J].重庆医科大学学报,2003(01):43-45. DOI： 10.13406/j.cnki.cyxb.2003.01.013.

LI Gang, et al. The serum levels of soluble Fas ligand and soluble Fas receptor in patients with chronic congestive heart failure[J]. Journal of Chongqing Medical University, 2003,(1):43-45. DOI： 10.13406/j.cnki.cyxb.2003.01.013.

摘要

目的:分析血清可溶性Fas配体（sFasL）和可溶性Fas。受体（sFas）与慢性心力衰竭（CHF）的相关性。方法:采用酶联免疫吸附双抗体夹心法检测33例CHF患者(CHF组

心功能Ⅱ-Ⅳ级

NYHA血清sFasL和sFas浓度

并与18例心功能Ⅰ级（NYHA）组比较。结果:CHF与心功能Ⅰ级组间sFasL浓度无显著统计学差异[231.50±84.50（心功能Ⅱ级216.50±96.00

Ⅲ级226.80±85.70Ⅳ级244.00±73.00）vs.217.50±89.00pg/ml

P>0.05]。而CHF组血清sFas浓度显著高于心功能Ⅰ级组[1353.30±507.71（心功能Ⅱ级1154.85±371.20

Ⅲ级1412.88±493.62

Ⅳ级1875.67±806.10）vs.983.11±461.26pg/ml

P<0.05]。结论:血清sFasL与CHF无相关性。而血清sFas与CHF存在显著相关性。且sFas浓度增高的程度与CHF的严重程度相平行

sFas浓度增高可能在CHF发病机制中起重要作用。

Abstract

Objective :To investigate the association of soluble Fas ligand (sFasL) and soluble Fas receptor (sFas) with human chronic congestive heart failure (CHF). Methods :The serum level of sFasL and sFas in 33 patients with CHF (13 in cardiac function class Ⅱ

17 in class Ⅲ

3 in class Ⅳ

NYHA) was assessed with enzyme- linked immunosorbent assay

and was compared with that of 18 age

gender and blood pressure - matched patients with cardiac function class Ⅰ (NYHA). Results: There was no difference in the level of sFasL between the two groups [ CHF group: 231. 50 ± 84. 50 (cardiac function class Ⅱ 216.50 ± 96.00

class Ⅲ 226.80 ± 85.70

claas Ⅳ 244.00 ± 73.00) vs. cardiac function class Ⅰ group: 217. 50 ± 89. 00 pg/ml

P > 0. 05 ]. However

the level of sFas was significantly higher in the patients with CHF than those of the cardiac function class Ⅰ group [CHF group: 1353. 30 ± 507. 71 (cardiac function class Ⅱ 1154. 85 ± 371.20

class Ⅲ 1412. 88 ± 493. 62

class Ⅳ 1875.67 ± 806. 10) vs. cardiac function class Ⅰ group:983. 11 ± 416.26 pg/ml

P<0. 05]. Conclusion :sFasL was not associated with human CHF. However

the elevation of serum level of sFas was proportionate to the severity of human CHF. sFas may play an important role in the pathogenesis of human CHF.

关键词

充血性心力衰竭Fas配体Fas受体可溶性

Keywords

Congestive heart failureSoluble Fas ligandSoluble Fas receptorSolubility

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

充血性心力衰竭患者的心率变异研究

充血性心力衰竭患者自主神经活性昼夜节律研究

缬沙坦在体外对充血性心力衰竭患者血清TNF-α的影响